How many insider trades does FilingIQ track for CDXS?

FilingIQ tracks 508 Form 4 insider transactions for CDXS (CODEXIS, INC.), covering filings from Feb 12, 2015 onwards. 0 of those are dated within the last 90 days.

Are CDXS insiders net buyers or net sellers?

Across the full Form 4 history for CDXS, 59 transactions (12%) were open-market purchases and 217 (43%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does CDXS insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.

What sector is CDXS in?

CODEXIS, INC. (CDXS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $105.68M.

CDXS insider trading

NasdaqGS Healthcare

CODEXIS, INC.: insider trade history from SEC Form 4 filings.

Total Form 4 trades

508

Last 90 days

Buys / sells

12% / 43%

Market cap

$105.68M

About CODEXIS, INC.

Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Company website: www.codexis.com

CDXS insider activity at a glance

FilingIQ tracks 508 insider transactions for CDXS in filings since Feb 12, 2015. The most recent transaction is dated Jun 11, 2026.

Across the full history, 59 open-market purchases and 217 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on CDXS insider trades is 47.4/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live CDXS trades on FilingIQ Raw filings on SEC EDGAR

Latest CDXS Form 4 filings

Lutz Stefan Chief Scientific Officer

SA Feb 25, 2026

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 820

UNITED THERAPEUTICS Corp

THERMO FISHER SCIENTIFIC INC.

NTRA 129

Natera, Inc.

ATTO 123

Attovia Therapeutics, Inc.

CORT 110

CORCEPT THERAPEUTICS INC

TEM 104

Tempus AI, Inc.

Frequently asked

How many insider trades does FilingIQ track for CDXS?: FilingIQ tracks 508 Form 4 insider transactions for CDXS (CODEXIS, INC.), covering filings from Feb 12, 2015 onwards. 0 of those are dated within the last 90 days.
Are CDXS insiders net buyers or net sellers?: Across the full Form 4 history for CDXS, 59 transactions (12%) were open-market purchases and 217 (43%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does CDXS insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
What sector is CDXS in?: CODEXIS, INC. (CDXS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $105.68M.

Methodology & sources

Every CDXS insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.